Children’s Hospital of Philadelphia Research Institute shared a post on LinkedIn:
“Following a Phase 3 study co-led by Children’s Hospital of Philadelphia researchers, children newly diagnosed with B-cell acute lymphoblastic leukemia can now receive an immunotherapy, blinatumomab, as part of their standard treatment plan.
The study, supported by the National Cancer Institute (NCI) and published in the New England Journal of Medicine, was led by the Children’s Oncology Group (COG), of which CHOP is a member.
‘It’s a safe, low-side-effect medication that is going to save a lot of kids’ lives,’ said David Teachey, MD, Chair of COG’s Acute Lymphoblastic Leukemia Disease Committee and Director of Clinical Research at CHOP’s Center for Childhood Cancer Research.
When paired with chemotherapy, blinatumomab increased patients’ three-year, disease-free survival rate from 88% to 96%.
